Glauprost
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Analogs
- 9. Terms and conditions of storage
- 10. Terms of dispensing from pharmacies
Glauprost is an antiglaucoma agent.
Release form and composition
Dosage form - eye drops: colorless, transparent (2.5 ml each in polymer dropper bottles, in a cardboard box 1 or 3 bottles).
Active substance: latanoprost, in 1 ml - 50 μg.
Auxiliary components: purified water, disodium hydrogen phosphate dodecahydrate, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate dihydrate.
Indications for use
Glauprost is used to reduce increased intraocular pressure in patients with ophthalmic hypertension and open-angle glaucoma.
Contraindications
- pregnancy;
- lactation;
- children's age up to 1 year;
- hypersensitivity to any component of the eye drops.
It is not recommended to use the drug for acute herpetic and chronic recurrent keratitis.
Glauprost should be used with caution in the following cases:
- aphakia;
- open-angle glaucoma in patients with pseudophakia;
- pseudophakia with rupture of the posterior capsule of the lens;
- anterior chamber intraocular lenses;
- congenital, inflammatory and neovascular glaucoma;
- pigmentary and angle-closure glaucoma;
- risk factors for the development of macular edema;
- acute attack of angle-closure glaucoma;
- secondary glaucoma due to inflammatory eye diseases;
- a history of herpetic keratitis;
- risk factors for the development of iritis / uveitis;
- postoperative period after cataract extraction;
- bronchial asthma.
Method of administration and dosage
Adults (including the elderly) and children over 1 year old are prescribed 1 drop in each affected eye 1 time per day. Instillation is recommended in the evening.
To reduce the possible systemic effect of latanoprost, immediately after instillation of each eye, press on the lower lacrimal opening for 1 minute (in the area of the inner corner of the eye on the lower eyelid).
Side effects
Gradation of side effects according to the frequency of their occurrence: very often -> 1/10, often - from ≥ 1/100 to <1/10, infrequently - from ≥ 1/1000 to <1/100, rarely - from ≥ 1/10 000 up to <1/1000, very rarely - <1/10 000, the frequency is unknown - it is not possible to estimate the incidence of these phenomena based on the available data.
Possible side effects:
- on the part of the organ of vision: very often - changes in eyelashes (an increase in the number, thickness, length, pigmentation), hyperpigmentation of the iris, eye irritation from mild to moderate (sensation of a foreign body or sand in the eyes, tingling, itching, burning sensation), hyperemia conjunctiva; often - eye pain, blepharitis, transient point erosion of the epithelium (usually asymptomatic); infrequently - blurred vision, dryness of the mucous membrane of the eye, conjunctivitis, keratitis, eyelid edema; rarely - periorbital edema, corneal edema, macular edema, photophobia, distichiasis, corneal erosion, iritis / uveitis (mainly in predisposed patients), change in the direction of eyelash growth; very rarely - changes in the periorbital region and the area of the eyelashes, leading to a deepening of the groove of the upper eyelid; frequency unknown - cyst of the iris;
- invasions and infections: frequency unknown - herpetic keratitis;
- from the respiratory system: rarely - shortness of breath, bronchospasm or exacerbation of the disease in patients with a history of bronchial asthma;
- on the part of the cardiovascular system: very rarely - aggravation of the course of the disease in patients with concomitant angina pectoris; frequency unknown - palpitations;
- from the nervous system: the frequency is unknown - headache, dizziness;
- from the musculoskeletal system: the frequency is unknown - arthralgia, myalgia;
- from the skin and subcutaneous tissues: infrequently - rash; rarely - local skin reactions on the eyelids, including darkening of the eyelid skin;
- others: very rarely - chest pain.
According to the results of two short-term clinical studies (up to 12 weeks), the safety profile of latanoprost in children does not differ from that in adults. Fever and nasopharyngitis were more common in children than in adults.
special instructions
As a preservative, Glauprost contains benzalkonium chloride, which can cause eye irritation, toxic ulcerative and / or punctate keratopathy, therefore, with prolonged use of the drug, it is necessary to carefully monitor the condition of patients with dry eye syndrome and other corneal diseases.
Also, benzalkonium chloride can be absorbed by soft contact lenses and discolor them, therefore it is recommended to remove the lenses before instilling drops and install them no earlier than 15 minutes.
In the case of the simultaneous appointment of other ophthalmic agents, at least 5-minute intervals should be observed between their applications.
By increasing the content of brown pigment in the iris, latanoprost can gradually change eye color. Before prescribing Glauprost, it is necessary to warn the patient about a possible irreversible change in eye color.
People who use drops to treat only one eye are likely to develop heterochromia. This is usually seen in patients with mixed iris coloration, such as yellow-brown, gray-brown, blue-brown, or green-brown. In the course of studies of long-term use of the drug, darkening in most cases began within the first 8 months of treatment, less often within 2 and 3 years, it was not noted after 4 years of therapy. The progression of iris pigmentation decreased over time and stabilized after 5 years.
In an open 5-year study of latanoprost, iris pigmentation developed in 33% of patients. In the overwhelming majority of cases, the color change was insignificant and not even clinically detected. The incidence in patients with mixed iris coloration ranges from 7–85% of cases and is predominant in patients with yellow-brown iris coloration.
Changes in patients with uniformly colored blue iris were not observed, in rare cases they were noted with uniformly colored irises of green, brown and gray.
Typically, brown pigmentation appears around the pupil that extends concentrically to the periphery of the iris. In this case, the entire iris or part of it becomes brown. After the end of treatment with Glauprost, further pigmentation did not occur. According to the available data, the color change is not associated with any pathological disorders and symptoms, and also does not lead to undesirable consequences. In this regard, when the iris darkens, the use of the drug can be continued, but it is recommended to monitor the patient's condition, if necessary, cancel the treatment.
Macular edema (including cystic edema) during the use of latanoprost was observed mainly in patients with rupture of the posterior lens capsule, pseudophakia, aphakia, as well as the presence of risk factors for the development of macular edema (retinal vein occlusion and diabetic retinopathy).
Drug interactions
There is no specific information on the drug interactions of latanoprost.
With simultaneous use with another analogue of prostaglandins, a paradoxical increase in intraocular pressure may be noted, therefore, such combinations should be avoided.
When Glauprost is prescribed in combination with other ophthalmic agents, 5-minute intervals must be observed between instillations.
Analogs
Glauprost analogs are: Xalatan, Xalatamax, Latanol, Prolatan.
Terms and conditions of storage
Store in a dark place, out of reach of children, at a temperature of 2-8 ° C.
Shelf life - 3 years, after the first opening of the bottle - 42 days at temperatures up to 25 ° C.
Terms of dispensing from pharmacies
Dispensed by prescription.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
